Tannic acid inhibits EGFR/STAT1/3 and enhances p38/STAT1 signalling axis in breast cancer cells

Journal of Cellular and Molecular Medicine

Volumn 21, Issue 4, 2017, Pages 720-734

  Darvin, Pramod ^a   Joung, Youn Hee ^a   Kang, Dong Young ^a   Sp, Nipin ^a   Byun, Hyo Joo ^a   Hwang, Tae Sook ^a   Sasidharakurup, Hema ^b   Lee, Chi Ho ^c   Cho, Kwang Hyun ^d   Park, Kyung Do ^e   Lee, Hak Kyo ^e   Yang, Young Mok ^a  

^a Konkuk University School of Medicine   (South Korea)

^b AMRITA UNIVERSITY   (India)

^c Konkuk University   (South Korea)

^d National Institute of Animal Science   (South Korea)

^e Chonbuk National University   (South Korea)

Author keywords

G1 arrest; p38 STAT1; STAT1 ser727; STAT3 BCl 2 mitochondrial apoptosis; tannic acid

Indexed keywords

CASPASE; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN BCL 2; PROTEIN SERINE KINASE; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN; SYNAPTOPHYSIN; TAMOXIFEN; TANNIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BINDING; QUINAZOLINE DERIVATIVE; TANNIN DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BREAST TUMOR; CELL NUCLEUS; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROMOTER REGION; PROTEIN TRANSPORT; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN TRANSPORT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TAMOXIFEN; TANNINS;

EID: 85003707710     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.13015     Document Type: Article

References (57)

1. Cancer Research UK. CancerStats. Worldwide cancer key facts, Cancer Research UK. 2013.
2. Park JH, Darvin P, Lim EJ, et al. Hwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through jak2/stat pathways in breast cancer xenografts. PLoS ONE. 2012; 7: e40531.
3. Darvin P, Joung YH, Sp N, et al. Sorghum polyphenol suppresses the growth as well as metastasis of colon cancer xenografts through co-targeting jak2/stat3 and pi3k/akt/mtor pathways. J Funct Foods. 2015; 15: 193–206.
4. Chen X, Beutler JA, McCloud TG, et al. Tannic acid is an inhibitor of CXCL12 (SDF-1α)/CXCR4 with antiangiogenic activity. Clin Cancer Res. 2003; 9: 3115–23.
5. Koide T, Kamei H, Hashimoto Y, et al. Tannic acid raises survival rate of mice bearing syngeneic tumors. Cancer Biother Radiopharm. 1999; 14: 231–4.
6. Alison SS. Use of tannic acid in various diseases. BMJ. 1850; s2-2: 1–9.
7. Chen KS, Hsiao YC, Kuo DY, et al. Tannic acid-induced apoptosis and -enhanced sensitivity to arsenic trioxide in human leukemia hl-60 cells. Leuk Res. 2009; 33: 297–307.
8. Gülçin İ, Huyut Z, Elmastaş M, et al. Radical scavenging and antioxidant activity of tannic acid. Arab J Chem. 2010; 3: 43–53.
9. Lavin SR, Chen Z, Abrams SA. Effect of tannic acid on iron absorption in straw-colored fruit bats (Eidolon helvum). Zoo Biol. 2010; 29: 335–43.
10. Yang EB, Wei L, Zhang K, et al. Tannic acid, a potent inhibitor of epidermal growth factor receptor tyrosine kinase. J Biochem. 2006; 139: 495–502.
11. Naus P, Henson R, Bleeker G, et al. Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol. 2007; 46: 222–9.
12. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by g1/s cyclin-dependent kinases. J Biol Chem. 1997; 272: 12738–46.
13. Hengst L, Göpfert U, Lashuel HA, et al. Complete inhibition of cdk/cyclin by one molecule of p21cip1. Genes Dev. 1998; 12: 3882–8.
14. Hengst L, Dulic V, Slingerland JM, et al. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA. 1994; 91: 5291–5.
15. Martine FR. The ink4 family of cell cycle inhibitors in cancer. Oncogene. 1999; 18: 5311–7.
16. Denicourt C, Dowdy SF. Cip/kip proteins: more than just cdks inhibitors. Genes Dev. 2004; 18: 851–5.
17. Pateras IS, Apostolopoulou K, Niforou K, et al. P57kip2: “Kip”ing the cell under control. Mol Cancer Res. 2009; 7: 1902–19.
18. Mantel C, Luo Z, Canfield J, et al. Involvement of p21cip-1 and p27kip-1 in the molecular mechanisms of steel factor-induced proliferative synergy in vitro and of p21cip-1 in the maintenance of stem/progenitor cells in vivo. Blood. 1996; 88: 3710–9.
19. Matsuura I, Denissova NG, Wang G, et al. Cyclin-dependent kinases regulate the antiproliferative function of smads. Nature. 2004; 430: 226–31.
20. Peñuelas S, Alemany C, Noé V, et al. The expression of retinoblastoma and sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors. Eur J Biochem. 2003; 270: 4809–22.
21. Harbour JW, Dean DC. The rb/e2f pathway: expanding roles and emerging paradigms. Genes Dev. 2000; 14: 2393–409.
22. Nevins JR. The rb/e2f pathway and cancer. Hum Mol Genet. 2001; 10: 699–703.
23. Opitz OG, Rustgi AK. Interaction between sp1 and cell cycle regulatory proteins is important in transactivation of a differentiation-related gene. Cancer Res. 2000; 60: 2825–30.
24. Edgar G, Franziska J, Inge W, et al. Sp1 as g1 cell cycle phase specific transcription factor in epithelial cells. Oncogene. 2002; 21: 1485–92.
25. Look DC, Pelletier MR, Tidwell RM, et al. Stat1 depends on transcriptional synergy with sp1. J Biol Chem. 1995; 270: 30264–7.
26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57–70.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–74.
28. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35: 495–516.
29. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001; 20: 2499–513.
30. Song JI, Grandis JR. Stat signaling in head and neck cancer. Oncogene. 2000; 19: 2489–95.
31. Pedranzini L, Leitch A, Bromberg J. Stat3 is required for the development of skin cancer. J Clin Invest. 2004; 114: 619–22.
32. Burke WM, Jin XH, Lin HJ, et al. Lin J Inhibition of constitutively active stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001; 20: 7925–34.
33. Laura KS, Zhiyong R, Gregory NF, et al. Constitutive activation of stat3α in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (vegfr-2). Oncogene. 2002; 21: 2058–65.
34. Lin J, Tang H, Jin X, et al. Hsieh JT P53 regulates stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active stat3. Oncogene. 2002; 21: 3082–8.
35. Yuan TL, Cantley CL. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 27: 5497–510.
36. Lim EJ, Hong DY, Park JH, et al. Methylsulfonylmethane suppresses breast cancer growth by down-regulating stat3 and stat5b pathways. PLoS ONE. 2012; 7: e33361.
37. Joung YH, Na YM, Yoo YB, et al. Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway. Int J Oncol. 2014; 44: 883–95.
38. Sp N, Darvin P, Yoo YB, et al. The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in er-positive breast cancer xenografts. BMC Cancer. 2015; 15: 474.
39. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27–55.
40. Timofeeva OA, Plisov S, Evseev AA, et al. Serine-phosphorylated stat1 is a prosurvival factor in wilms’ tumor pathogenesis. Oncogene. 2006; 25: 7555–64.
41. Saramäki A, Banwell CM, Campbell MJ, et al. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin d3 receptor. Nucleic Acids Res. 2006; 34: 543–54.
42. Davis NM, Sokolosky M, Stadelman K, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014; 5: 4603–50.
43. Zhu X, Wen Z, Xu LZ, et al. Stat1 serine phosphorylation occurs independently of tyrosine phosphorylation and requires an activated jak2 kinase. Mol Cell Biol. 1997; 17: 6618–23.
44. Kim SH, Kim SY, Park EJ, et al. Icilin induces G1 arrest through activating Jnk and p38 kinase in a trpm8-independent manner. Biochem Biophys Res Commun. 2011; 406: 30–5.
45. Hawkes WC, Alkan Z. Delayed cell cycle progression in selenoprotein W-depleted cells is regulated by a mitogen-activated protein kinase kinase 4 (mkk4)-p38/c-jun NH2-terminal kinase (jnk)-p53 pathway. J Biol Chem. 2012; 287: 27371–9.
46. Kovarik P, Stoiber D, Eyers PA, et al. Stress-induced phosphorylation of stat1 at ser727 requires p38 mitogen-activated protein kinase whereas IFN-γ uses a different signaling pathway. Proc Natl Acad Sci USA. 1999; 96: 13956–61.
47. Pardee A. G1 events and regulation of cell proliferation. Science. 1989; 246: 603–8.
48. Chin YE, Kitagawa M, Su WC, et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science. 1996; 272: 719–22.
49. kip1. PLoS ONE. 2008; 3: e3476.
50. Imada K, Leonard WJ. The jak-STAT pathway. Mol Immunol. 2000; 37: 1–11.
51. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999; 98: 295–303.
52. Chen YB, Aon MA, Hsu YT, et al. Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential. J Cell Biol. 2011; 195: 263–76.
53. Jiang X, Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem. 2000; 275: 31199–203.
54. Mori T, Rezai-Zadeh K, Koyama N, et al. Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem. 2012; 287: 6912–27.
55. Samanta S, Giri S, Parua S, et al. Impact of tannic acid on the gastrointertinal microflora. Microb Ecol Health Dis. 2004; 16: 32–4.
56. Akomolafe SF, Akinyemi AJ, Anadozie SO. Phenolic Acids (Gallic and Tannic Acids) Modulate Antioxidant Status and Cisplatin Induced Nephrotoxicity in Rats. Int Sch Res Notices. 2014; 2014: 984709.
57. Mittal DK, Joshi D, Shukla S. Protective effects of polygonum bistorta (linn.) and its active principle against acetaminophen-induced toxicity in rats. Asian J Exp Biol Sci. 2010; 1: 951–8.